Sai Parenterals (SAIPARENT) had a P/E of 82.7× on 6 Nov 2026, above the industry P/E of 37.3×, and the shares are 34% below their 52-week high. Sales and net profit grew 58% and 48% a year over 3 years, with ROCE of 3.6% and ROE of 4.9%. Debt is 0.49× equity. It is a small-cap company with a market cap of ₹2,060 Cr, ranked 11th of 15 Drug Manufacturers (General) companies by market cap; the shares rose 15% over the past year.
- ₹480.00
- ₹480.00
- ₹463.00
- ₹482.95
- 1.2 L
Health check
- ReturnsIn line
+14.9% over a year, better than 3 of 7 peers.
- Price tagPricier
P/E 82.7 vs industry 37.3.
- GrowthStrong
Sales +57.9%, profit +48.2% a year over 3 years.
- ProfitabilityWeak
ROCE 3.6% vs peer median 23.3%.
- Balance sheetFair
Debt 0.49× equity, interest covered 1.6×, Piotroski 5 of 9.
- Red flags4 to check
Return on equity is low at 4.9%.
Small cap
Market sensitivity
Key metrics
- Market cap
- ₹2,060 Cr
- Small cap
- P/E
- 82.7
- Industry 37.3
- Price to book
- 4.20
- Peers 18.55
- Dividend yield
- 0.00%
- ROE
- 4.9%
- Peers 20.9%
- ROCE
- 3.6%
- Peers 23.3%
- Debt to equity
- 0.49
- Debt ₹243 Cr
- EPS (TTM)
- ₹5.64
- Face value ₹5
- OPM (TTM)
- 17.4%
- Net margin 3.9%
- Sales growth
- +264.1%
- Latest quarter vs a year ago
- Profit growth
- +65.5%
- Latest quarter vs a year ago
- Price to sales
- 3.91
- EV/EBITDA 40.4
Strengths and risks
Strengths
- Quarterly profit up 65.5% on a year ago.
- Quarterly sales up 264.1% on a year ago.
Risks to check
- Return on equity is low at 4.9%.
- P/E of 82.7 against an industry P/E of 37.3.
- 34% below its 52-week high.
- Interest coverage of only 2.1×.
About Sai Parenterals
Sai Parenteral's Limited, a pharmaceutical formulations company, engages in the branded generic formulations and contract development and manufacturing businesses in India and internationally. Its portfolio includes formulation products across various therapeutic areas, such as cardiovascular, neuropsychiatry, anti-diabetic, respiratory health, antibiotics, gastroenterology, vitamins, minerals and supplements, analgesics, oncology, and dermatology in…
- Headquarters
- Hyderabad
- Employees
- 293
- Sector
- Healthcare
- ISIN
- INE0H9F01037
- Website
- saiparenterals.com
Price range
- Avg volume (3M)
- 1.3 L
- 1-year return
- plus 14.9%
- From 52-week high
- minus 33.9%
Peers · Drug Manufacturers - General
| Company | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| GLAXOGlaxosmithkline Pharmaceuticals | 2,524.80 | plus 0.98% | 42,772 | 37.3 | 22.73 | 55.4% | 63.9% | 34.1% | 5.7% | 19.3% | 2.26% | minus 6.0% |
| RUBICONRubicon Research | 1,659.30 | minus 4.67% | 27,468 | 95.6 | 19.38 | 23.6% | 19.1% | 23.3% | – | – | 0.09% | plus 166.7% |
| PFIZERPfizer | 3,856.00 | minus 0.02% | 17,640 | 23.2 | 4.02 | 22.9% | 20.9% | 36.7% | 1.3% | 5.0% | 1.94% | minus 24.6% |
| CORONACORONA Remedies | 2,441.10 | plus 2.58% | 14,930 | 72.1 | 18.55 | 29.0% | 28.3% | 21.3% | 16.6% | 29.7% | 0.41% | plus 69.7% |
| MARKSANSMarksans Pharma | 303.70 | minus 3.20% | 13,764 | 24.6 | 4.13 | 17.5% | 15.2% | 22.5% | 16.7% | 16.2% | 0.30% | plus 68.0% |
| SYMBIOTECSymbiotec Pharmalab | 1,513.60 | plus 19.04% | 9,726 | 103.5 | 8.26 | 14.3% | 11.2% | 10.7% | 16.8% | 67.3% | 0.00% | plus 37.9% |
| SANOFICONRSanofi Consumer Healthcare India | 3,420.20 | minus 0.69% | 7,888 | 28.2 | 22.64 | – | 80.4% | 37.8% | – | – | 2.19% | minus 29.5% |
| SAIPARENTSai Parenterals | 466.35 | minus 3.44% | 2,060 | 82.7 | 4.20 | 3.6% | 4.9% | 8.6% | 57.9% | 48.2% | 0.00% | plus 14.9% |
| Median of 7 peers | – | −0.02% | 14,930 | 37.3 | 18.55 | 23.3% | 20.9% | 23.3% | 16.6% | 19.3% | 0.41% | 37.9% |
Quarterly results
| ₹ Cr | Jun 25 | Sep 25 | Jun 26 | Sep 26 |
|---|---|---|---|---|
| 33.4 | 53.5 | 179 | 195 | |
| – | – | +435.1% | +264.1% | |
| 28.6 | 42.1 | 155 | 155 | |
| 4.7 | 11.4 | 23.5 | 40.2 | |
| 14.2% | 21.3% | 13.2% | 20.6% | |
| 1.2 | 1.3 | 3.7 | 3.7 | |
| 2.5 | 2.2 | 9.4 | 9 | |
| 1.4 | 1.4 | 8.1 | 25.1 | |
| 2 | 9.2 | 9.8 | 9.9 | |
| 29.4% | 30.6% | 19.1% | −6.3% | |
| 2.8 | 6.4 | 15.8 | 10.5 | |
| – | – | +459.9% | +65.5% | |
| 0.64 | 1.44 | 1.79 | 2.38 |
Profit & loss
- Sales CAGR 3Y
- +57.9%
- Profit CAGR 3Y
- +48.2%
- EPS CAGR 3Y
- +48.2%
- ROE
- 4.9%
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 96.8 | 154 | 163 | 381 | |
| – | +58.9% | +6.1% | +133.6% | |
| 74.5 | 119 | 118 | 341 | |
| 22.3 | 34.8 | 44.6 | 39.6 | |
| 23.1% | 22.7% | 27.4% | 10.4% | |
| −0.9 | 1.5 | −0.1 | 9.9 | |
| 5.7 | 11.1 | 11.9 | 18.4 | |
| 5.8 | 9.4 | 8.2 | 16.9 | |
| −2.7 | −3.3 | −4.5 | −2.2 | |
| 7.3 | 12.6 | 19.9 | 11.9 | |
| 39.7% | 33.0% | 27.5% | −19.5% | |
| 4.4 | 8.4 | 14.5 | 14.3 | |
| – | +92.3% | +71.8% | minus 1.3% | |
| 0.99 | 1.90 | 3.27 | 3.23 |
Forecast
Balance sheet
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| 7.2 | 13.2 | 13.3 | 22.1 | |
| 24.3 | 61.3 | 80.4 | 469 | |
| 68.5 | 119 | 94 | 469 | |
| 33.9 | 74.8 | 84.8 | 465 | |
| 134 | 268 | 272 | 1,424 | |
| 47.3 | 65.4 | 49 | 410 | |
| 3.8 | 5.4 | 5.7 | 219 | |
| 1.1 | 0.7 | 1.3 | 2.1 | |
| 0.2 | 4.4 | 2.1 | 417 | |
| 81.6 | 192 | 214 | 376 | |
| 134 | 268 | 272 | 1,424 |
Cash flow
| ₹ Cr | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|
| −12.8 | −29.8 | 33.1 | 93.1 | |
| −19 | −46.3 | 0.4 | −274 | |
| 24 | 78.6 | −35.9 | 596 | |
| −7.9 | 2.5 | −2.3 | 415 | |
| −17.3 | −44.1 | −0.5 | −277 | |
| −30.1 | −73.9 | 32.6 | −184 |
Shareholding pattern
- Promoters51.16%
- Public48.84%
| Quarter | Split | Promoters | Public | Promoter change |
|---|---|---|---|---|
| 30 Sep 2026 | 51.16% | 48.84% | 0.00 | |
| 30 Jun 2026 | 51.16% | 48.84% | 0.00 | |
| 1 Apr 2026 | 51.16% | 48.84% | 0.00 | |
| 31 Mar 2026 | 51.16% | 48.84% | – |
Major shareholders
Filings & events
News
No recent news coverage found.